Cytosorbents (CTSO) 10-Q 12 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 07, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'Cytosorbents Corp	'
Entity Central Index Key	'0001175151	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	581,820,005

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash and cash equivalents	$433,423	$2,183,030
Grants and accounts receivable, net of allowance for doubtful accounts of $3,236 at September 30, 2014 and $-0- at December 31, 2013	561,964	453,017
Short-term investments	7,346,994	'
Inventories	387,075	245,608
Prepaid expenses and other current assets	225,004	605,312
Total current assets	8,954,460	3,486,967
Property and equipment - net	191,127	144,393
Other assets	481,017	414,375
Total long-term assets	672,144	558,768
Total Assets	9,626,604	4,045,735
Current Liabilities:	'	'
Accounts payable	446,167	786,517
Accrued expenses and other current liabilities	445,110	361,700
Deferred revenue	3,333	272,359
Warrant liability	654,840	'
Convertible notes payable, net of debt discount in the amount of $0 at September 30, 2014 and $198,644 at December 31, 2013	'	1,644,356
Total current liabilities	1,549,450	3,064,932
Series B 10% Cumulative Convertible Preferred Stock, par value $0.001, 200,000 Shares authorized; 84,283.99 and 79,336.54 issued and outstanding at September 30, 2014 and December 31, 2013, respectively	18,874,241	15,246,350
Stockholders' Equity/ (Deficiency):	'	'
Series A 10% Cumulative Convertible Preferred Stock, 12,000,000 shares authorized; 1,894,969 and 1,759,666 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	1,895	1,760
Common Stock, 800,000,000 shares authorized; 322,775,473 and 251,319,547 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	322,775	251,320
Additional paid-in capital	102,713,676	91,343,135
Accumulated other comprehensive income (loss)	67,196	-55,987
Accumulated deficit	-113,902,629	-105,805,775
Total stockholders' equity (deficiency)	-10,797,087	-14,265,547
Total Liabilities and Stockholders' Equity (Deficiency)	$9,626,604	$4,045,735

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Allowance for doubtful accounts	$3,236	0
Convertible notes payable current, debt discount	$0	198,644
Common Stock, Par Value	$0.00	'
Common Stock, shares authorized	800,000,000	800,000,000
Common Stock, shares issued	322,775,473	251,319,547
Common Stock, shares outstanding	322,775,473	251,319,547
Series B 10% Cumulative Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par Value	$0.00	0.001
Preferred Stock, shares authorized	200,000	200,000
Preferred Stock, shares issued	84,283.99	79,336.54
Preferred Stock, shares outstanding	84,283.99	79,336.54
Series A 10% Cumulative Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par Value	$0.00	'
Preferred Stock, shares authorized	12,000,000	12,000,000
Preferred Stock, shares issued	1,894,969	1,759,666
Preferred Stock, shares outstanding	1,894,969	1,759,666

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue:	'	'	'	'
Sales	$1,031,761	$203,561	$2,264,237	$507,628
Grant income	128,087	677,131	978,271	1,035,877
Other revenue	2,499	'	6,666	'
Total revenue	1,162,347	880,692	3,249,174	1,543,505
Cost of revenue	475,890	620,623	1,804,578	1,073,689
Gross profit	686,457	260,069	1,444,596	469,816
Other Expenses:	'	'	'	'
Research and development	880,292	294,198	1,464,059	1,706,498
Legal, financial and other consulting	182,996	157,926	733,056	570,465
Selling, general and administrative	1,309,519	687,788	3,471,138	1,901,768
Total expenses	2,372,807	1,139,912	5,668,253	4,178,731
Loss from operations	-1,686,350	-879,843	-4,223,657	-3,708,915
Other (income)/expense:	'	'	'	'
Interest expense/(income), net	46,600	84,946	311,458	299,805
Change in warrant liability	-234,600	'	-208,080	'
Total other (income) expense, net	-188,000	84,946	103,378	299,805
Loss before benefit from income taxes	-1,498,350	-964,789	-4,327,035	-4,008,720
Benefit from income taxes	'	'	'	'
Net loss	-1,498,350	-964,789	-4,327,035	-4,008,720
Preferred stock dividend	1,281,058	525,148	3,769,819	1,728,053
Net loss available to common shareholders	-2,779,408	-1,489,937	-8,096,854	-5,736,773
Basic and diluted net loss per common share	($0.01)	($0.01)	($0.03)	($0.02)
Weighted average number of shares of common stock outstanding	312,400,345	242,512,486	293,189,313	232,426,316
Net loss	-1,498,350	-964,789	-4,327,035	-4,008,720
Other comprehensive loss:	'	'	'	'
Currency translation adjustment	118,032	40,184	123,183	36,915
Comprehensive loss	($1,380,318)	($924,605)	($4,203,852)	($3,971,805)

CONSOLIDATED_STATEMENT_OF_CHAN

CONSOLIDATED STATEMENT OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIENCY) (USD $)	Total	Common Stock [Member]	Series B Preferred Stock [Member]	Series A Preferred Stock [Member]	Additional Paid In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2013	($14,265,547)	$251,320	$15,246,350	$1,760	$91,343,135	($55,987)	($105,805,775)
Balance, shares at Dec. 31, 2013	'	251,319,547	79,336.54	1,759,666	'	'	'
Stock based compensation - employees, consultants and directors	150,273	'	'	'	150,273	'	'
Issuance of common stock for services rendered	180,100	1,123	'	'	178,977	'	'
Issuance of common stock for services rendered, shares	1,123,033	1,123,033	'	'	'	'	'
Issuance of Series A Preferred Stock as dividends	'	'	'	135	26,148	'	-26,283
Issuance of Series A Preferred Stock as dividends, shares	'	'	'	135,303	'	'	'
Issuance of Series B Preferred Stock as dividends	-3,743,536	'	3,743,536	'	'	'	-3,743,536
Issuance of Series B Preferred Stock as dividends, shares	'	'	6,072.18	'	'	'	'
Conversion of Series A & B Preferred Stock as dividends	115,645	3,107	-115,645	'	112,538	'	'
Conversion of Series A & B Preferred Stock as dividends, shares	'	3,106,988	-1,124.73	'	'	'	'
Issuance of common stock for cash	300,000	2,483	'	'	297,517	'	'
Issuance of common stock for cash, shares	'	2,483,399	'	'	'	'	'
Issuance of common stock - offering	10,200,000	40,800	'	'	10,159,200	'	'
Issuance of common stock - offering, shares	'	40,800,000	'	'	'	'	'
Conversion of convertible notes to common	1,990,440	17,533	'	'	1,972,907	'	'
Conversion of convertible notes to common, shares	'	17,532,720	'	'	'	'	'
Cost of raising capital	-748,545	'	'	'	-748,545	'	'
Other comprehensive income/(loss): foreign translation adjustment	123,183	'	'	'	'	123,183	'
Cashless exercise of warrants	'	3,958	'	'	-3,958	'	'
Cashless exercise of warrants, shares	'	3,958,716	'	'	'	'	'
Exercise of stock options	90,855	2,451	'	'	88,404	'	'
Exercise of stock options (in shares)	2,466,300	2,451,070	'	'	'	'	'
Warrant liability	-862,920	'	'	'	-862,920	'	'
Net loss	-4,327,035	'	'	'	'	'	-4,327,035
Balance at Sep. 30, 2014	($10,797,087)	$322,775	$18,874,241	$1,895	$102,713,676	$67,196	($113,902,629)
Balance, shares at Sep. 30, 2014	'	322,775,473	84,283.99	1,894,969	'	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($4,327,035)	($4,008,720)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Issuance of common stock to consultant for services	180,100	65,468
Depreciation and amortization	70,449	47,573
Amortization of debt discount	198,644	228,468
Bad debt expense	3,236	'
Expense for issuance of options	150,273	300,105
Change in warrant liability	-208,080	'
Changes in operating assets and liabilities:	'	'
Grants and accounts receivable	-112,183	-142,094
Inventories	-141,467	319,830
Prepaid expenses and other current assets	380,308	318,438
Other assets	-4,568	9,442
Accounts payable and accrued expenses	-109,500	38,989
Deferred revenue	-269,026	435,686
Net cash used by operating activities	-4,188,849	-2,386,815
Cash flows from investing activities:	'	'
Purchases of property and equipment	-89,495	-33,276
Patent costs	-89,762	-18,861
Purchases of short-term investments	-7,346,994	'
Net cash used by investing activities	-7,526,251	-52,137
Cash flows from financing activities:	'	'
Equity contributions - net of fees incurred	9,751,455	1,599,967
Proceeds from borrowings	'	1,263,000
Proceeds from exercise of stock options	90,855	20,194
Proceeds from exercise of warrants	'	139,526
Net cash provided by financing activities	9,842,310	3,022,687
Effect of exchange rates on cash	123,183	36,915
Net change in cash and cash equivalents	-1,749,607	620,650
Cash and cash equivalents - beginning of period	2,183,030	1,729,344
Cash and cash equivalents - end of period	433,423	2,349,994
Supplemental disclosure of cash flow information:	'	'
Cash paid during the period for interest	'	'
Supplemental schedule of noncash investing and financing activities:	'	'
Increase in other current assets through the issuance of convertible debt	'	580,000
Fair value of warrant liability upon issuance	862,920	'
Debt discount in connection with issuance of convertible debt	'	331,117
Fair value of shares issued as costs of raising capital	7,137	34,034
Note payable principal and interest conversion to equity	1,990,440	1,226,042
Costs paid from proceeds in conjunction with issuance of common stock and preferred stock	748,545	'
Preferred stock dividends	$3,769,819	$1,728,053

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (Series B Preferred Stock Conversion Common Stock [Member] Series B Preferred Stock [Member], USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
			Common Stock [Member]	Common Stock [Member]
Preferred Shares converted into Common shares	1,124.73	198.27	'	'
Common shares issued upon conversion	'	'	3,106,988	547,707
Preferred Stock, Par Value	$0.00	$0.00	'	'
Common Stock, Par Value	'	'	'	$0.00

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2014
BASIS OF PRESENTATION [Abstract]	'
BASIS OF PRESENTATION	'
		1	BASIS OF PRESENTATION
	The accompanying unaudited interim consolidated financial statements have been prepared in accordance with the requirements of Form 10-Q of the Securities and Exchange Commission (the “Commission”) and include the results of CytoSorbents Corporation (the “Parent”), CytoSorbents, Inc. (as of October 28, 2014, known as CytoSorbents Medical, Inc.), its wholly-owned operating subsidiary (the “Subsidiary”), and CytoSorbents Europe GmbH, its wholly-owned European subsidiary (the “European Subsidiary”), collectively referred to as “the Company.”
	Accordingly, certain information and footnote disclosures required in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. Interim statements are subject to possible adjustments in connection with the annual audit of the Company's accounts for the year ended December 31, 2014. In the opinion of the Company's management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) which the Company considers necessary for the fair presentation of the Company's consolidated financial position as of September 30, 2014 and the results of its operations and cash flows for the nine and three month periods ended September 30, 2014 and 2013. Results for the nine months ended September 30, 2014 and 2013 are not necessarily indicative of results that may be expected for the entire year. The unaudited interim consolidated financial statements should be read in conjunction with the audited financial statements of the Company and the notes thereto as of and for the year ended December 31, 2013 as included in the Company's Form 10-K filed with the Commission on March 31, 2014.
	The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has experienced negative cash flows from operations since inception. The Company is not currently generating significant revenue and is dependent on the proceeds of present and future offerings to fund its research, development and commercialization program. The Company currently has adequate funding for more than the next twelve months of operations; however, it may have to raise additional capital to fund future operations. Although the Company has historically been successful in raising additional capital through equity and debt offerings, there can be no assurance that the Company will be successful in raising additional capital in the future or that it will be on favorable terms. Furthermore, if the Company is successful in raising the additional offering, there can be no assurance that the amount will be sufficient to complete the Company's plans. These matters raise substantial doubt about the Company's ability to continue as a going concern. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.
	Since inception, the Company's expenses relate primarily to research and development, organizational activities, clinical manufacturing, regulatory compliance and operational strategic planning. Although the Company has made advances on these matters, there can be no assurance that the Company will continue to be successful regarding these issues, nor can there be any assurance that the Company will successfully implement its long-term strategic plans.

PRINCIPAL_BUSINESS_ACTIVITY_AN

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2014
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
		2	PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
	Nature of Business
	The Company, through its subsidiary CytoSorbents, Inc. (as of October 28, 2014, known as CytoSorbents Medical, Inc.), is engaged in the research, development and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The Company, through CytoSorbents Europe, GmbH, its European subsidiary, has commenced initial sales and marketing related operations for the CytoSorb® device in the European Union. The Company is focused on developing this technology for multiple applications in the medical field, specifically to provide improved blood purification for the treatment of acute and chronic health complications associated with blood toxicity. In March 2011, the Company received CE Mark approval for its CytoSorb® device.
	The technology is based upon biocompatible, highly porous polymer sorbent beads that are capable of extracting unwanted substances from blood and other bodily fluids. The technology is protected by 32 issued U.S. patents with multiple patent applications pending both in the U.S. and internationally. Our intellectual property consists of composition of matter, materials, methods of production systems incorporating the technology, and multiple medical uses with expiration dates ranging from 3 to 12 years.
	Principles of Consolidation
	The consolidated financial statements include the accounts of CytoSorbents Corporation, the Parent, and its wholly-owned subsidiaries, CytoSorbents, Inc. (as of October 28, 2014, known as CytoSorbents Medical, Inc.) and CytoSorbents Europe GmbH. All significant intercompany transactions and balances have been eliminated in consolidation.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
	Grants and Accounts Receivable
	Grants receivable represent amounts due from U.S. government agencies. Accounts receivable are unsecured, non-interest bearing customer obligations due under normal trade terms. The Company sells its devices to various hospitals and distributors. The Company performs ongoing credit evaluations of customers' financial condition. Management reviews accounts receivable periodically to determine collectability. Balances that are determined to be uncollectible are written off to the allowance for doubtful accounts. The allowance for doubtful accounts contains a general accrual for estimated bad debts and had a balance of $3,236 at September 30, 2014 and $-0- at December 31, 2013.
	Short-Term Investments
	Short-term investments include certificates of deposit with original maturities of greater than three months. The cost of the certificates of deposit approximates fair value.
	Inventories
	Inventories are valued at the lower of cost or market. At September 30, 2014 and December 31, 2013, the Company's inventory was comprised of finished goods, which amounted to approximately $101,000 and $107,000, respectively; work in process which amounted to approximately $250,000 and $101,000, respectively; and raw materials, which amounted to approximately $36,000 and $38,000, respectively. Devices used in clinical trials or for research and development purposes are removed from inventory and charged to research and development expenses at the time of their use.
	Property and Equipment
	Property and equipment are recorded at cost less accumulated depreciation. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the lesser of their economic useful lives or the term of the related leases. Gains and losses on depreciable assets retired or sold are recognized in the statements of operations in the year of disposal. Repairs and maintenance expenditures are expensed as incurred.
	Patents
	Legal costs incurred to establish and successfully defend patents are capitalized. When patents are issued, capitalized costs are amortized on the straight-line method over the related patent term. In the event a patent is abandoned, the net book value of the patent is written off.
	Impairment or Disposal of Long-Lived Assets
	The Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value.
	Warrant Liability
	The Company recognizes the fair value of the warrants as of the date of the warrant grant using the binomial lattice valuation model. At each subsequent reporting date, the Company again measures the fair value of the warrants, and records a change to the warrant liability as appropriate, and the change is reported in the statement of operations.
	Revenue Recognition
	Product Sales: Revenues from sales of products are recognized at the time of delivery when title and risk of loss passes to the customer. Recognition of revenue also requires reasonable assurance of collection of sales proceeds and completion of all performance obligations.
	Grant Revenue: Revenue from grant income is based on contractual agreements. Certain agreements provide for reimbursement of costs, while other agreements provide for reimbursement of costs and an overhead margin. Revenues are recognized when milestones have been achieved and revenues have been earned. Costs are recorded as incurred. Costs subject to reimbursement by these grants have been reflected as costs of revenue.
	Deferred Revenue: The Company defers revenue that has been received but not yet earned on government contracts and product sales. This revenue will be recognized as income in the period in which the revenue is earned. All deferred revenue is expected to be earned within one year of the balance sheet date.
	Research and Development
	All research and development costs, payments to laboratories and research consultants are expensed when incurred.
	Advertising Expenses
	Advertising costs are charged to activities when incurred. Advertising expenses amounted to approximately $94,000 and $30,000 for the nine months ended September 30, 2014 and 2013, respectively, and is included in selling, general, and administrative expenses on the consolidated statement of operations.
	Income Taxes
	Income taxes are accounted for under the asset and liability method prescribed by accounting standards for accounting for income taxes. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized. Under Section 382 of the Internal Revenue Code, the net operating losses generated prior to the reverse merger may be limited due to the change in ownership. Additionally, net operating losses generated subsequent to the reverse merger may be limited in the event of changes in ownership.
	The Company follows accounting standards associated with uncertain tax positions. The Company had no unrecognized tax benefits at September 30, 2014 or December 31, 2013. The Company files tax returns in the U.S. federal and state jurisdictions. The Company currently has no open years prior to December 31, 2010 and has no income tax related penalties or interest for the periods presented in these financial statements.
	The Company's European subsidiary, CytoSorbents Europe GmbH annually files a corporate tax return, VAT return and a trade tax return in Germany.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, the valuation of preferred shares issued as stock dividends, valuation methods used to determine the fair value of the warrant liability, and valuation methods used in determining any debt discount associated with convertible securities.
	Concentration of Credit Risk
	The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.
	As of September 30, 2014, four distributors, and one hospital accounted for approximately 64% of outstanding grant and accounts receivable. At December 31, 2013, one U.S. government agency accounted for approximately 66% of outstanding accounts receivable. For the nine months ended September 30, 2014, approximately 19% of revenues were from one U.S. government agency, and no other agency, distributor, or direct customer represented more than 10% of the Company's revenue. For the nine months ended September 30, 2013, approximately 67% of revenues were from two U.S. government grant agencies, and no other agency, distributor, or direct customer represented more than 10% of the Company's revenue.
	Financial Instruments
	The carrying values of cash and cash equivalents, short-term investments, accounts payable, notes payable, and other debt obligations approximate their fair values due to their short-term nature.
	Net Loss Per Common Share
	Basic EPS is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period. The computation of Diluted EPS does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings (See Note 7).
	Stock-Based Compensation
	The Company accounts for its stock-based compensation under the recognition requirements of accounting standards for accounting for stock-based compensation, for employees and directors whereby each option granted is valued at fair market value on the date of grant. Under these accounting standards, the fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model.
	The Company also follows the guidance of accounting standards for accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants.
	Effects of Recent Accounting Pronouncements
	Accounting Standards Update (“ASU”) 2014-10, which for public business entities will be effective for annual reporting periods beginning after December 15, 2014 and interim periods therein, removes the definition of a development stage entity from the Accounting Standards Codification, thereby eliminating the financial reporting distinction between development stage entities from U.S. GAAP. Specifically eliminated are the requirements to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development state entity that in prior years it had been in the development stage. The Company has adopted ASU 2014-10 within its September 30, 2014 financial statements.
	In May 2014, the Financial Account Standards Board (“FASB”) issued ASU 2014-09, “Revenue with Contracts from Customers.” ASU 2014-09 supercedes the current revenue recognition guidance, including industry-specific guidance. The ASU introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The updated guidance is effective for public entities for interim and annual periods beginning after December 15, 2016 and early adoption is not permitted. The Company is currently evaluating the impact of the updated guidance, but the Company does not believe that the adoption of ASU 2014-09 will have a significant impact on its consolidated financial statements.
	Shipping and Handling Costs
	The costs of shipping product to customers and distributors is typically borne by the customer or distributor. The Company records other shipping and handling costs in Research and Development. Total freight costs amounted to approximately $77,000 and $17,000 for the nine months ended September 30, 2014 and September 30, 2013, respectively.

CONVERTIBLE_NOTES

CONVERTIBLE NOTES	9 Months Ended
	Sep. 30, 2014
CONVERTIBLE NOTES [Abstract]	'
CONVERTIBLE NOTES	'
		3	CONVERTIBLE NOTES
	On June 21, 2013 (the “June Closing Date”), the Company issued convertible notes to certain accredited investors (the “June Purchasers”), whereby the Company agreed to sell and the June Purchasers agreed to purchase the convertible notes in the aggregate principal amount of $1,098,000 (the “June Notes”). The June Notes were to mature one (1) year from the June Closing Date (the “June Maturity Date”), bear interest at an annual rate of 8%, and automatically convert into shares of the Company's Common Stock at a conversion price of $0.125 at maturity or earlier at the option of the June Purchaser. In connection with the issuance of the June Notes, the Company issued warrants to purchase shares of Common Stock, providing 50% coverage, exercisable at $0.15 per share (the “June Warrants”). On June 21, 2014, all outstanding June Notes were converted into 9,486,720 shares of Common Stock, consisting of 8,784,000 shares related to the principal value of the June Notes and 702,720 shares of Common Stock for payment of interest earned on the June Notes.
	On September 30, 2013 (the “September Closing Date”), the Company issued convertible notes to certain accredited investors (the “September Purchasers”), whereby the Company agreed to sell and the September Purchasers agreed to purchase the convertible notes in the aggregate principal amount of $745,000 (the “September Notes”). The September Notes were to mature one (1) year from the September Closing Date (the “September Maturity Date”), bear interest at an annual rate of 8%, and automatically convert into shares of Common Stock, at a conversion price of $0.10 at maturity or earlier at the option of the September Purchaser. In connection with the issuance of the September Notes, the Company issued warrants to purchase shares of Common Stock, providing 50% coverage, exercisable at $0.125 per share (the “September Warrants”). On September 30, 2014, all outstanding September Notes were converted into 7,450,000 shares of Common Stock related to the principal value of the September Notes and 596,000 shares of Common Stock for payment of interest earned on the September Notes.
	The Company allocates the proceeds associated with the issuance of convertible notes based on the relative fair value of the convertible notes and warrants. Additionally, the Company evaluates if the embedded conversion option results in a beneficial conversion feature by comparing the relative fair value allocated to the convertible notes to the market value of the underlying Common Stock subject to conversion. In connection with the convertible note issuances during the years ended December 31, 2013, the Company received proceeds of $1,843,000. The Company allocated the proceeds in accordance with FASB Codification Topic 470 based on the related fair value as follows: $1,511,883 was allocated to the convertible notes and $171,012 to the warrants. Additionally, the embedded conversion feature resulted in a beneficial conversion feature in the amount of $160,105. The value assigned to the warrants resulting from the relative fair value calculation as well as the value of the beneficial conversion feature is recorded as a debt discount and is presented in the consolidated balance sheets. The debt discount has been amortized to interest expense over the term of the convertible notes. During the nine months ended September 30, 2014 and 2013, debt discount of approximately $199,000 and $228,000, respectively, was charged to interest expense.

STOCKHOLDERS_EQUITY_DEFICIT

STOCKHOLDERS' EQUITY (DEFICIT)	9 Months Ended
	Sep. 30, 2014
STOCKHOLDERS' EQUITY (DEFICIT) [Abstract]	'
STOCKHOLDERS' EQUITY (DEFICIT)	'
		4	STOCKHOLDERS' EQUITY (DEFICIT)
	On March 7, 2014, the Company entered into subscription agreements with certain investors providing for the issuance and sale by the Company (the “Offering”) of 40,800,000 units (the “Units”) for an aggregate purchase price of $10,200,000.  Each Unit is comprised of one share of Common Stock, priced at $0.25 per share, and a warrant to purchase 0.50 shares of Common Stock at an exercise price of $0.3125 per share. The warrants are convertible into a total of 20,400,000 shares of Common Stock. Each warrant is exercisable for a period of five (5) years beginning on March 11, 2014, the date of the closing of the sale of the Units, is only exercisable for cash, and is only exercisable if there is an effective registration statement registering the warrants and shares underlying the warrants. The Common Stock underlying these warrants were registered in the registration statement on Form S-1 (File No. 333-193053), which was declared effective by the Commission on February 14, 2014 and an additional registration statement on Form S-1 (File No. 333-194394).
	The Company received net proceeds from the Offering of approximately $9,451,000 million. The net proceeds received by the Company from the Offering is being used for building additional sales and marketing infrastructure, clinical studies, working capital and general corporate purposes.
	The Company conducted the Offering pursuant to a registration statement on Form S-1 (File No. 333-193053), which was declared effective by the Commission on February 14, 2014 and an additional registration statement on Form S-1 (File No. 333-194394) to register an additional amount of securities having a proposed maximum aggregate offering price of $2,762,500, which increased the total registered amount to $16,575,000 assuming the full cash exercise of the warrants for cash. The Company filed a final prospectus on March 7, 2014, disclosing the final terms of the Offering.
	In connection with the Offering, on March 7, 2014, the Company entered into a placement agency agreement with Brean Capital, LLC, pursuant to which Brean Capital, LLC agreed to act as the Company's exclusive placement agent (the “Placement Agent”) for the Offering and sale of the Units.
	In connection with the successful completion of the Offering, the Placement Agent received an aggregate cash placement agent fee equal to 6% of the gross proceeds of the sale of the Units in the Offering, or $612,000, and a warrant to purchase 1,224,000 shares of Common Stock at an exercise price of $0.30 per share exercisable for five years from the effective date of the placement agency agreement (the “Placement Agent Warrant”). The Placement Agent Warrant contains piggy-back registration rights which expire on the fifth anniversary of the effective date of the registration statement. The Company has also agreed to reimburse the Placement Agent for actual out-of-pocket expenses up to a maximum of 2% of gross proceeds from the transaction. The Company also granted the Placement Agent a right of first refusal to participate in any subsequent offering or placement of its securities that takes place within twelve months following the effective date of the registration statement.
	During the nine months ended September 30, 2014, the Company recorded non-cash stock dividends totaling $3,769,819 in connection with the issuance of 6,072.18 shares of Series B Preferred Stock and 135,303 shares of Series A Preferred Stock as stock dividends to its preferred shareholders.
	During the nine months ended September 30, 2014, the Company incurred stock-based compensation expense due to the issuance of stock options, and amortization of unvested stock options. The aggregate expense for the nine months ended September 30, 2014 is approximately $150,000, of which approximately $130,000 was recorded in general and administrative expenses and approximately $20,000 was recorded as research and development expenses.
	The summary of the stock option activity for the nine months ended September 30, 2014 is as follows:
							Weighted
							Average			Weighted
							Exercise			Average
							Price			Remaining
			Shares				per Share			Life (Years)
	Outstanding, January 1, 2014			47,923,642			$	0.2			5.1
	Granted			16,135,000			$	0.2			9.1
	Cancelled			(5,695,250	)		$	0.13			7.6
	Exercised			(2,466,300	)		$	0.04			3.6
	Expired			(51,809	)		$	0.83			—
	Outstanding September 30, 2014			55,845,283			$	0.21			6.3
	The fair value of each stock option was estimated using the Black-Scholes pricing model which takes into account as of the grant date the exercise price (ranging from $0.195 to $0.274 per share) and expected life of the stock option (ranging from 5-10 years), the current price of the underlying stock and its expected volatility (approximately 28%), expected dividends on the stock (0%) and the risk free interest rate (0.8 to 2.1%) for the term of the stock option.
	At September 30, 2014, the aggregate intrinsic value of options outstanding and currently exercisable amounted to approximately $3,552,000.
	The summary of the status of the Company's non-vested options for the six months ended September 30, 2014 is as follows:
							Weighted
							Average
							Grant
							Date
			Shares				Fair Value
	Non-vested, January 1, 2014			13,418,000			$	0.034
	Granted			16,135,000			$	0.058
	Cancelled			(4,861,250	)		$	0.033
	Vested			(2,412,250	)		$	0.044
	Non-vested, September 30, 2014			22,279,500			$	0.051
	As of September 30, 2014, the Company had approximately $159,000 of total unrecognized compensation cost related to stock options. In March 2014, the Board of Directors set aside a pool of 14,010,000 options to be awarded to the Company's employees if the Company achieves certain specific, predetermined milestones. The grant date fair value of these unvested options amounted to approximately $791,000. Due to the uncertainty over whether these options will vest, which only occurs if the Company meets the predetermined milestones, no charge for these options has been recorded in the consolidated statements of operations for the nine months ended September 30, 2014. The Company will evaluate on an ongoing basis the probability and likelihood of any of these performance milestones being achieved and will accrue charges as it becomes likely that they will be achieved.
	As of September 30, 2014, the Company has the following warrants to purchase Common Stock outstanding:
	Number of Shares				Warrant				Warrant
					Exercise
	To be Purchased				Price per Share				Expiration Date
		1,750,000			$	0.1			16-Aug-15
		1,600,000			$	0.125			16-Aug-15
		1,333,333			$	0.15			16-Aug-15
		490,000			$	0.1			22-Oct-15
		196,000			$	0.125			22-Oct-15
		163,333			$	0.15			22-Oct-15
		500,000			$	0.1			19-Nov-15
		200,000			$	0.125			19-Nov-15
		166,667			$	0.15			19-Nov-15
		700,000			$	0.1			15-Feb-16
		1,540,000			$	0.125			15-Feb-16
		1,416,666			$	0.15			15-Feb-16
		240,125			$	1.25			24-Oct-16
		1,166,667			$	0.175			10-Feb-17
		4,392,000			$	0.15			21-Jun-18
		3,725,000			$	0.125			30-Sep-18
		20,400,000			$	0.3125			11-Mar-19
		1,224,000			$	0.3			11-Mar-19
		41,203,791
	In addition, during the nine months ended September 30, 2014, the Company issued 1,123,033 shares of Common Stock valued at $180,100 to a vendor for consulting services, 2,466,300 options were exercised for 2,451,070 shares of Common Stock, and warrants to purchase 6,460,000 shares of Common Stock were exercised for 3,958,716 shares of Common Stock. On June 21, 2014, $1,098,000 in convertible notes matured. In accordance with the terms of the notes, the note holders were issued 9,486,720 shares of Common Stock which included 8,784,000 shares of Common Stock for payment of the convertible notes and 702,720 shares representing payment of interest accrued on the convertible notes. On September 30, 2014, $745,000 in convertible notes matured.
	In accordance with the terms of the notes, the note holders were issued 8,046,000 shares of Common Stock which included 7,450,000 share of Common Stock for payment of the convertible notes and 596,000 shares representing payment of interest accrued on the convertible notes.
	In December 2011, the Company terminated a purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”) and executed a new purchase agreement (the “New Purchase Agreement”), and a registration rights agreement with LPC. Under the New Purchase Agreement, LPC is obligated, under certain conditions, to purchase from the Company up to $8.5 million of its Common Stock, from time to time, over a thirty-two (32) month period.
	Under the New Purchase Agreement, the Company had the right, but not the obligation, to direct LPC to purchase up to $8,500,000 of its Common Stock in amounts up to $50,000 as often as every two business days under certain conditions. The Company could also accelerate the amount of its Common Stock to be purchased under certain circumstances. No sales of Common Stock could occur at a purchase price below $0.10 per share or without a registration statement having been declared effective. The purchase price of the Common Stock was based on the market prices of the Company's Common Stock at the time of sale as computed under the New Purchase Agreement without any fixed discount. The Company had the right at any time at its sole discretion to terminate the New Purchase Agreement without fee, penalty or cost upon one business days' notice.
	There was no up-front commitment fee paid to LPC for entering into the New Purchase Agreement. In the event the Company directs LPC to purchase up to $8,500,000 of its Common Stock, the Company would have been obligated to issue up to an additional 1,634,615 commitment fee shares of Common Stock on a pro rata basis. LPC could not assign any of its rights or obligations under the New Purchase Agreement.
	During the nine months ended September 30, 2014 the Company received approximately $300,000 as proceeds from the sale of 2,425,709 shares of Common Stock per the terms of the New Purchase Agreement with LPC at an average price of approximately $0.124 per share of Common Stock. Per the terms of the New Purchase Agreement, the Company also issued an additional 57,690 shares of Common Stock as additional commitment fee shares.
The Company has not sold any shares of its Common Stock under the New Purchase Agreement since January 17, 2014. The New Purchase Agreement expired pursuant to its terms in August 2014. At the time of expiration, $2,400,000 remained unused under the new Purchase Agreement with LPC.

WARRANT_LIABILITY

WARRANT LIABILITY	9 Months Ended
	Sep. 30, 2014
WARRANT LIABILITY [Abstract]	'
WARRANTY LIABILITY	'
		5	WARRANT LIABILITY
	In connection with its March 11, 2014 offering, the Company issued warrants to purchase 20,400,000 shares of Common Stock. The Company recognizes these warrants as liabilities at their fair value on the date of grant, then measures the fair value of the warrants on each reporting date, and records a change to the warrant liability as appropriate. The warrants have certain pricing provisions which apply if the Company sells or issues Common Stock or Common Stock equivalents at a price that is less than the exercise price of the warrants, over the life of the warrants, excluding certain exempt issuances.
	The Company recognized an initial warrant liability for the warrants issued in connection with the Offering completed in March 2014. The initial warrant liability recognized on the related warrants totaled $862,920, which was based on the March 11, 2014 five-day weighted average closing price per share of the Company's Common Stock of $0.24. On September 30, 2014, the five day weighted average closing price per share of Common Stock was $0.224. Due to the fluctuations in the market value of the Company's Common Stock from March 11, 2014 through September 30, 2014, the Company recorded a change in the fair value of the warrant liability of $208,080 during the nine months ended September 30, 2014.
	The assumptions used in connection with the valuation of warrants issued utilizing the binomial lattice valuation model were as follows:
			September 30,			Initial
			2014			Measurement
						March 11,
						2014
	Number of shares underlying the warrants			20,400,000			20,400,000
	Exercise price		$	0.3125		$	0.3125
	Volatility			28.3	%		28.3	%
	Risk-free interest rate			1.6	%		1.62	%
	Expected dividend yield			0			0
	Expected warrant life (years)			4.44			5
	Stock Price		$	0.224		$	0.24

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2014
COMMITMENTS AND CONTINGENCIES [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
		6	COMMITMENTS AND CONTINGENCIES
	Employment Agreements
	The Company is currently in the process of renewing employment agreements with certain key executives.
	Litigation
	We are from time to time subject to claims and litigation arising out of the ordinary course of business. We intend to defend vigorously against any future claims and litigation. We are not currently a party to any legal proceedings.
	Royalty Agreements
	Pursuant to an agreement dated August 11, 2003, an existing investor agreed to make a $4 million equity investment in the Company. These amounts were received by the Company in 2003. In connection with this agreement, the Company granted the investor a future royalty of 3% on all gross revenues received by the Company from the sale of its CytoSorb® device. For the nine months ended September 30, 2014 the Company has recorded royalty costs of approximately $68,000.
	License Agreements
	In September 2006, the Company entered into a license agreement which provides the Company the exclusive right to use its patented technology and proprietary know how relating to adsorbent polymers for a period of 18 years. Under the terms of the agreement, the Company has agreed to pay royalties of 2.5% to 5% on the sale of certain of its products if and when those products are sold commercially for a term not greater than 18 years commencing with the first sale of such product. For the nine months ended September 30, 2014 per the terms of the license agreement the Company has recorded royalty costs of approximately $57,000.
	Warrant Agreement
	As inducement to invest additional funds in the private placement of Series B Preferred Stock, additional consideration was granted to the participants of the Series B Preferred Stock offering in the event that litigation is commenced against the Company prior to June 30, 2018, claiming patent infringement on certain of the Company's issued patents. In the event this litigation arose the Company may have been required to issue warrants to purchase in the aggregate up to a maximum of ten million shares of Common Stock subject to certain adjustments. Through September 30, 2014 no such litigation has arisen and the Company has not booked a contingent liability for this agreement. On October 9, 2014, all the shares of Series B Preferred Stock were converted into Common Stock (see Note 8, Subsequent Events), and therefore this additional consideration is no longer applicable.

NET_LOSS_PER_SHARE

NET LOSS PER SHARE	9 Months Ended
	Sep. 30, 2014
NET LOSS PER SHARE [Abstract]	'
NET LOSS PER SHARE	'
		7	NET LOSS PER SHARE
	Basic loss per share and diluted loss per share for the three months ended September 30, 2014 and 2013 have been computed by dividing the net loss for each respective period by the weighted average number of shares outstanding during that period.
	All outstanding warrants and options representing approximately 97,049,000 and 74,289,000 incremental shares at September 30, 2014 and 2013, respectively, as well as shares issuable upon conversion of Series A and Series B Preferred Stock representing approximately 234,478,000 and 215,310,000 incremental shares at September 30, 2014 and 2013, respectively, as well as potential shares issuable upon Note conversion into Common Stock representing approximately 0 and 16,234,000 incremental shares at September 30, 2014 and 2013, respectively, have been excluded from the computation of diluted loss per share as they are anti-dilutive.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2014
SUBSEQUENT EVENTS [Abstract]	'
SUBSEQUENT EVENTS	'
		8	SUBSEQUENT EVENTS
	Conversion of Series A and Series B Preferred Stock into Common Stock.
	On October 9, 2014, the Company filed with the Nevada Secretary of State an Amendment (the "Series A Amendment") to the Certificate of Designation, as amended (the "Series A Certificate of Designation") of the Series A Preferred Stock. The Series A Amendment, which became effective on October 9, 2014, (i) amended the Series A Certificate of Designation to allow the stockholders representing eighty percent (80%) of the issued and outstanding shares of Series A Preferred Stock to elect to convert all issued and outstanding shares of Series A Preferred Stock into Common Stock of the Company, $0.001 par value per share (the "Common Stock"), at the then-effective "Conversion Price," as defined in the Series A Certificate of Designation, and (ii) as consideration for approving such amendment, amended the Conversion Price from $1.25 per share to $0.77 per share, except with respect to the shares of Series A Preferred Stock covered by that certain Agreement and Consent dated as of June 25, 2008 by and among the Company and certain holders of Series A Preferred Stock. Immediately following effectiveness of the Series A Amendment, the stockholders representing over 88 percent (88%) of the then-issued and outstanding Series A Preferred Stock elected to convert all issued and outstanding Series A Preferred Stock into Common Stock at the Conversion Price, as amended. As a result of this election by the holders of Series A Preferred Stock, 1,894,969 shares of Series A Preferred Stock were converted into 2,583,289 shares of Common Stock.
	In addition, on October 9, 2014, the Company also filed with the Nevada Secretary of State an Amendment (the "Series B Amendment") to the Certificate of Designation (the "Series B Certificate of Designation") of the Series B Preferred Stock. The Series B Amendment, which became effective on October 9, 2014, amended the Series B Certificate of Designation to allow the holders of a majority of the Series B Preferred Stock, including NJTC Investment Fund, LP, to elect to convert all issued and outstanding shares of Series B Preferred Stock into Common Stock. Immediately following effectiveness of the Series B Amendment, the stockholders representing over 93 percent (93%) of the then-issued and outstanding Series B Preferred Stock elected to convert all issued and outstanding Series B Preferred Stock into Common Stock. Each share of Series B Preferred Stock had a stated value of $100.00 (the "Series B Stated Value"), and was convertible into that number of shares of Common Stock equal to the Series B Stated Value at a conversion price of $0.036. As consideration for approving the Series B Amendment the holders of Series B Preferred Stock received a one-time dividend equal to ten percent (10%) of the shares of Series B Preferred Stock then held. As a result of this election by the holders of Series B Preferred Stock, 84,283.99 shares of Series B Preferred Stock were issued a dividend of 10% and then the 92,712.27 were converted into 256,111,243 shares of Common Stock. As a result of the conversion, the carrying value of the Series B stock was reclassified to permanent equity.
	After giving effect to the conversions of the Series A Preferred Stock and Series B Preferred Stock described above, there are no shares of Preferred Stock of the Company issued and outstanding.
	Proposed Corporate Actions Subject to Stockholder Consent.
	The Company previously announced its intention to up-list its Common Stock to a national exchange by the end of calendar year 2014. In order to facilitate that process, on November 6, 2014, the Company sought stockholder consent authorizing its Board of Directors to (i) amend the Company's Articles of Incorporation, as amended, to effect a reverse split of its Common Stock, with a reverse split ratio of twenty five-to-one; (ii) amend its Articles of Incorporation, as amended, to reduce the total number of authorized shares of Common Stock from 800,000,000 to 50,000,000, after giving effect to the reverse stock split; (iii) amend its Articles of Incorporation, as amended, to reduce the total number of authorized shares of undesignated preferred stock from 100,000,000 to 5,000,000, after giving effect to the reverse stock split; (iv) implement the form, terms and provisions of the CytoSorbents Corporation 2014 Long-Term Incentive Plan; and (v) change the domicile of the Company from the State of Nevada to the State of Delaware through a merger with and into a newly-organized, wholly-owned subsidiary of the Company which was organized under the laws of the State of Delaware. Assuming such proposals are approved by stockholders, the Company intends to implement such corporate actions in December 2014. There can be no assurances that the stockholders will approve any of the above corporate actions, including the merger, or that the Company will receive approval to list its Common Stock on a national exchange.
	Subsidiaries.
	On October 28, 2014, the Company formed CytoSorbents Corporation, a wholly-owned subsidiary of the Company, with the Secretary of State of Delaware in order to facilitate the merger discussed above. On the same day, the Company changed the name of its U.S. subsidiary, CytoSorbents, Inc., to CytoSorbents Medical, Inc. with the Secretary of State of Delaware.

PRINCIPAL_BUSINESS_ACTIVITY_AN1

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2014
PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]	'
Nature of Business	'
	Nature of Business
	The Company, through its subsidiary CytoSorbents, Inc. (as of October 28, 2014, known as CytoSorbents Medical, Inc.), is engaged in the research, development and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The Company, through CytoSorbents Europe, GmbH, its European subsidiary, has commenced initial sales and marketing related operations for the CytoSorb® device in the European Union. The Company is focused on developing this technology for multiple applications in the medical field, specifically to provide improved blood purification for the treatment of acute and chronic health complications associated with blood toxicity. In March 2011, the Company received CE Mark approval for its CytoSorb® device.
	The technology is based upon biocompatible, highly porous polymer sorbent beads that are capable of extracting unwanted substances from blood and other bodily fluids. The technology is protected by 32 issued U.S. patents with multiple patent applications pending both in the U.S. and internationally. Our intellectual property consists of composition of matter, materials, methods of production systems incorporating the technology, and multiple medical uses with expiration dates ranging from 3 to 12 years.
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of CytoSorbents Corporation, the Parent, and its wholly-owned subsidiaries, CytoSorbents, Inc. (as of October 28, 2014, known as CytoSorbents Medical, Inc.) and CytoSorbents Europe GmbH. All significant intercompany transactions and balances have been eliminated in consolidation.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Grants and Accounts Receivable	'
	Grants and Accounts Receivable
	Grants receivable represent amounts due from U.S. government agencies. Accounts receivable are unsecured, non-interest bearing customer obligations due under normal trade terms. The Company sells its devices to various hospitals and distributors. The Company performs ongoing credit evaluations of customers' financial condition. Management reviews accounts receivable periodically to determine collectability. Balances that are determined to be uncollectible are written off to the allowance for doubtful accounts. The allowance for doubtful accounts contains a general accrual for estimated bad debts and had a balance of $3,236 at September 30, 2014 and $-0- at December 31, 2013.
Short-Term Investments	'
	Short-Term Investments
	Short-term investments include certificates of deposit with original maturities of greater than three months. The cost of the certificates of deposit approximates fair value.
Inventories	'
	Inventories
	Inventories are valued at the lower of cost or market. At September 30, 2014 and December 31, 2013, the Company's inventory was comprised of finished goods, which amounted to approximately $101,000 and $107,000, respectively; work in process which amounted to approximately $250,000 and $101,000, respectively; and raw materials, which amounted to approximately $36,000 and $38,000, respectively. Devices used in clinical trials or for research and development purposes are removed from inventory and charged to research and development expenses at the time of their use.
Property and Equipment	'
	Property and Equipment
	Property and equipment are recorded at cost less accumulated depreciation. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the lesser of their economic useful lives or the term of the related leases. Gains and losses on depreciable assets retired or sold are recognized in the statements of operations in the year of disposal. Repairs and maintenance expenditures are expensed as incurred.
Patents	'
	Patents
	Legal costs incurred to establish and successfully defend patents are capitalized. When patents are issued, capitalized costs are amortized on the straight-line method over the related patent term. In the event a patent is abandoned, the net book value of the patent is written off.
Impairment or Disposal of Long-Lived Assets	'
	Impairment or Disposal of Long-Lived Assets
	The Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value.
Warrant Liability	'
	Warrant Liability
	The Company recognizes the fair value of the warrants as of the date of the warrant grant using the binomial lattice valuation model. At each subsequent reporting date, the Company again measures the fair value of the warrants, and records a change to the warrant liability as appropriate, and the change is reported in the statement of operations.
Revenue Recognition	'
	Revenue Recognition
	Product Sales: Revenues from sales of products are recognized at the time of delivery when title and risk of loss passes to the customer. Recognition of revenue also requires reasonable assurance of collection of sales proceeds and completion of all performance obligations.
	Grant Revenue: Revenue from grant income is based on contractual agreements. Certain agreements provide for reimbursement of costs, while other agreements provide for reimbursement of costs and an overhead margin. Revenues are recognized when milestones have been achieved and revenues have been earned. Costs are recorded as incurred. Costs subject to reimbursement by these grants have been reflected as costs of revenue.
	Deferred Revenue: The Company defers revenue that has been received but not yet earned on government contracts and product sales. This revenue will be recognized as income in the period in which the revenue is earned. All deferred revenue is expected to be earned within one year of the balance sheet date.
Research and Development	'
	Research and Development
	All research and development costs, payments to laboratories and research consultants are expensed when incurred.
Advertising Expenses	'
	Advertising Expenses
	Advertising costs are charged to activities when incurred. Advertising expenses amounted to approximately $94,000 and $30,000 for the nine months ended September 30, 2014 and 2013, respectively, and is included in selling, general, and administrative expenses on the consolidated statement of operations.
Income Taxes	'
	Income Taxes
	Income taxes are accounted for under the asset and liability method prescribed by accounting standards for accounting for income taxes. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized. Under Section 382 of the Internal Revenue Code, the net operating losses generated prior to the reverse merger may be limited due to the change in ownership. Additionally, net operating losses generated subsequent to the reverse merger may be limited in the event of changes in ownership.
	The Company follows accounting standards associated with uncertain tax positions. The Company had no unrecognized tax benefits at September 30, 2014 or December 31, 2013. The Company files tax returns in the U.S. federal and state jurisdictions. The Company currently has no open years prior to December 31, 2010 and has no income tax related penalties or interest for the periods presented in these financial statements.
	The Company's European subsidiary, CytoSorbents Europe GmbH annually files a corporate tax return, VAT return and a trade tax return in Germany.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, the valuation of preferred shares issued as stock dividends, valuation methods used to determine the fair value of the warrant liability, and valuation methods used in determining any debt discount associated with convertible securities.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.
	As of September 30, 2014, four distributors, and one hospital accounted for approximately 64% of outstanding grant and accounts receivable. At December 31, 2013, one U.S. government agency accounted for approximately 66% of outstanding accounts receivable. For the nine months ended September 30, 2014, approximately 19% of revenues were from one U.S. government agency, and no other agency, distributor, or direct customer represented more than 10% of the Company's revenue. For the nine months ended September 30, 2013, approximately 67% of revenues were from two U.S. government grant agencies, and no other agency, distributor, or direct customer represented more than 10% of the Company's revenue.
Financial Instruments	'
	Financial Instruments
	The carrying values of cash and cash equivalents, short-term investments, accounts payable, notes payable, and other debt obligations approximate their fair values due to their short-term nature.
Net Loss Per Common Share	'
	Net Loss Per Common Share
	Basic EPS is computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period. The computation of Diluted EPS does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings (See Note 7).
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company accounts for its stock-based compensation under the recognition requirements of accounting standards for accounting for stock-based compensation, for employees and directors whereby each option granted is valued at fair market value on the date of grant. Under these accounting standards, the fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model.
	The Company also follows the guidance of accounting standards for accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants.
Effects of Recent Accounting Pronouncements	'
	Effects of Recent Accounting Pronouncements
	Accounting Standards Update (“ASU”) 2014-10, which for public business entities will be effective for annual reporting periods beginning after December 15, 2014 and interim periods therein, removes the definition of a development stage entity from the Accounting Standards Codification, thereby eliminating the financial reporting distinction between development stage entities from U.S. GAAP. Specifically eliminated are the requirements to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development state entity that in prior years it had been in the development stage. The Company has adopted ASU 2014-10 within its September 30, 2014 financial statements.
	In May 2014, the Financial Account Standards Board (“FASB”) issued ASU 2014-09, “Revenue with Contracts from Customers.” ASU 2014-09 supercedes the current revenue recognition guidance, including industry-specific guidance. The ASU introduces a five-step model to achieve its core principal of the entity recognizing revenue to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The updated guidance is effective for public entities for interim and annual periods beginning after December 15, 2016 and early adoption is not permitted. The Company is currently evaluating the impact of the updated guidance, but the Company does not believe that the adoption of ASU 2014-09 will have a significant impact on its consolidated financial statements.
Shipping and Handling Costs	'
	Shipping and Handling Costs
	The costs of shipping product to customers and distributors is typically borne by the customer or distributor. The Company records other shipping and handling costs in Research and Development. Total freight costs amounted to approximately $77,000 and $17,000 for the nine months ended September 30, 2014 and September 30, 2013, respectively.

STOCKHOLDERS_EQUITY_DEFICIT_Ta

STOCKHOLDERS' EQUITY (DEFICIT) (Tables)	9 Months Ended
	Sep. 30, 2014
STOCKHOLDERS' EQUITY (DEFICIT) [Abstract]	'
Summary of Stock Option Activity	'
	The summary of the stock option activity for the nine months ended September 30, 2014 is as follows:
							Weighted
							Average			Weighted
							Exercise			Average
							Price			Remaining
			Shares				per Share			Life (Years)
	Outstanding, January 1, 2014			47,923,642			$	0.2			5.1
	Granted			16,135,000			$	0.2			9.1
	Cancelled			(5,695,250	)		$	0.13			7.6
	Exercised			(2,466,300	)		$	0.04			3.6
	Expired			(51,809	)		$	0.83			—
	Outstanding September 30, 2014			55,845,283			$	0.21			6.3
Summary of Status of Non-Vested Options	'
	The summary of the status of the Company's non-vested options for the six months ended September 30, 2014 is as follows:
							Weighted
							Average
							Grant
							Date
			Shares				Fair Value
	Non-vested, January 1, 2014			13,418,000			$	0.034
	Granted			16,135,000			$	0.058
	Cancelled			(4,861,250	)		$	0.033
	Vested			(2,412,250	)		$	0.044
	Non-vested, September 30, 2014			22,279,500			$	0.051
Warrants to Purchase Common Stock	'
	As of September 30, 2014, the Company has the following warrants to purchase Common Stock outstanding:
	Number of Shares				Warrant				Warrant
					Exercise
	To be Purchased				Price per Share				Expiration Date
		1,750,000			$	0.1			16-Aug-15
		1,600,000			$	0.125			16-Aug-15
		1,333,333			$	0.15			16-Aug-15
		490,000			$	0.1			22-Oct-15
		196,000			$	0.125			22-Oct-15
		163,333			$	0.15			22-Oct-15
		500,000			$	0.1			19-Nov-15
		200,000			$	0.125			19-Nov-15
		166,667			$	0.15			19-Nov-15
		700,000			$	0.1			15-Feb-16
		1,540,000			$	0.125			15-Feb-16
		1,416,666			$	0.15			15-Feb-16
		240,125			$	1.25			24-Oct-16
		1,166,667			$	0.175			10-Feb-17
		4,392,000			$	0.15			21-Jun-18
		3,725,000			$	0.125			30-Sep-18
		20,400,000			$	0.3125			11-Mar-19
		1,224,000			$	0.3			11-Mar-19
		41,203,791

WARRANT_LIABILITY_Tables

WARRANT LIABILITY (Tables)	9 Months Ended
	Sep. 30, 2014
WARRANT LIABILITY [Abstract]	'
Schedule of Warrant Liability	'
	The assumptions used in connection with the valuation of warrants issued utilizing the binomial lattice valuation model were as follows:
		September 30,			Initial
		2014			Measurement
					March 11,
					2014
	Number of shares underlying the warrants		20,400,000			20,400,000
	Exercise price	$	0.3125		$	0.3125
	Volatility		28.3	%		28.3	%
	Risk-free interest rate		1.6	%		1.62	%
	Expected dividend yield		0			0
	Expected warrant life (years)		4.44			5
	Stock Price	$	0.224		$	0.24

PRINCIPAL_BUSINESS_ACTIVITY_AN2

PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	9 Months Ended			9 Months Ended			12 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2013
				Minimum [Member]	Maximum [Member]	Accounts receivable [Member]	Accounts receivable [Member]	Revenue [Member]	Revenue [Member]
Concentration Risk [Line Items]	'	'	'	'	'	'	'	'	'
Inventory of finished goods	$101,000	'	$107,000	'	'	'	'	'	'
Inventory of work in progress	250,000	'	101,000	'	'	'	'	'	'
Inventory of raw materials	36,000	'	38,000	'	'	'	'	'	'
Accounts receivable, allowance for doubtful accounts	3,236	'	0	'	'	'	'	'	'
Concentration risk percentage	'	'	'	'	'	64.00%	66.00%	19.00%	67.00%
Advertising	94,000	30,000	'	'	'	'	'	'	'
Shipping and handling expenses	$77,000	$17,000	'	'	'	'	'	'	'
Number of patents issued	32	'	'	'	'	'	'	'	'
Amortization Period	'	'	'	'3 years	'12 years	'	'	'	'

CONVERTIBLE_NOTES_Details

CONVERTIBLE NOTES (Details) (USD $)	1 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2013	Jun. 21, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Mar. 11, 2014	Mar. 07, 2014
Debt Instrument [Line Items]	'	'	'	'	'	'	'
Promissory notes, aggregate principal amount	$745,000	$1,098,000	'	$745,000	'	'	'
Promissory note, maturity period	'1 year	'1 year	'	'	'	'	'
Number of shares underlying the warrants	'	'	20,400,000	'	'	20,400,000	20,400,000
Promissory note, convertible, conversion price per share	$0.13	$0.13	'	$0.13	'	'	'
Percentage of principal amount used to calculate shares of common stock for warrant coverage	50.00%	50.00%	'	50.00%	'	'	'
Exercise price of warrant	$0.10	$0.15	'	'	'	'	'
Fair value of convertible notes	'	'	'	'	1,511,883	'	'
Fair value of warrants	'	'	'	'	171,012	'	'
Debt instrument, beneficial conversion feature	'	'	'	'	160,105	'	'
Interest rate	8.00%	8.00%	'	'	'	'	'
Common shares issued in exchange for convertible notes	'	9,486,720	8,046,000	'	'	'	'
Interest expense	'	'	199,000	228,000	'	'	'
Proceeds from borrowings	'	'	'	$1,263,000	$1,843,000	'	'
Purchasers Note [Member]	'	'	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'	'	'
Common shares issued in exchange for convertible notes	'	8,784,000	7,450,000	'	'	'	'
Interest [Member]	'	'	'	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'	'	'	'
Common shares issued in exchange for convertible notes	'	702,720	596,000	'	'	'	'

STOCKHOLDERS_EQUITY_DEFICIT_Na

STOCKHOLDERS' EQUITY (DEFICIT) (Narrative) (Details) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

Mar. 07, 2014

Mar. 11, 2014

Jun. 21, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Feb. 14, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Jun. 21, 2013

Sep. 30, 2014

Jun. 21, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2011

Sep. 30, 2014

Aug. 31, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2014

Stock Options [Member]

Maximum [Member]

Minimum [Member]

Research and development [Member]

General and administrative [Member]

Purchasers Note [Member]

Purchasers Note [Member]

Interest [Member]

Interest [Member]

Common Stock [Member]

Warrant [Member]

Lincoln Park Capital Fund, LLC [Member]

New Purchase Agreement [Member]

New Purchase Agreement [Member]

Series A 10% Cumulative Convertible Preferred Stock [Member]

Series A 10% Cumulative Convertible Preferred Stock [Member]

Series A 10% Cumulative Convertible Preferred Stock [Member]

Redeemable Preferred Stock [Member]

Stock Options [Member]

Stock Options [Member]

Stockholders Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, shares authorized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,000,000

12,000,000

'

'

Issuance of Series B Preferred Stock as dividends, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,072.18

Issuance of Series A Preferred Stock as dividends, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

135,303

'

'

'

Preferred stock dividend

'

'

'

$1,281,058

$525,148

$3,769,819

$1,728,053

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible preferred stock, conversion price

$0.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

'

$0.00

'

Preferred stock, conversion, percent of stated value

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of preferred shares converted

40,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common shares issues upon conversion

20,400,000

20,400,000

'

20,400,000

'

20,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price

$0.31

$0.31

'

$0.31

'

$0.31

'

'

'

$0.27

$0.20

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected warrant life (years)

'5 years

'5 years

'

'

'

'4 years 5 months 8 days

'

'

'

'10 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Volatility

'

28.30%

'

'

'

28.30%

'

'

28.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected dividend yield

'

0.00%

'

'

'

0.00%

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk free interest rate, minimum

'

'

'

'

'

'

'

'

0.80%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk free interest rate, maximum

'

'

'

'

'

'

'

'

2.10%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options outstanding and exercisable

'

'

'

3,552,000

'

3,552,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to stock option

'

'

'

159,000

'

159,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Non-vested options expected to vest

'

'

'

'

'

14,010,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Grant date fair value of these unvested options

'

'

'

791,000

'

791,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of convertible notes to common share

10,200,000

'

'

'

'

1,990,440

1,226,042

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase agreement, amount of shares

16,575,000

'

'

'

'

'

'

2,762,500

'

'

'

'

'

'

'

'

'

'

'

8,500,000

'

'

'

'

'

'

Period for purchase of common stock under agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'32 months

'

'

'

'

'

'

Amount of shares that can be sold as often as every two business days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

Issuance price of common stock per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.10

'

'

'

'

'

'

Number of business days in which up to $50,000 amount of stock can be sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'

'

'

Issuance of common stock for cash, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,483,399

'

'

2,425,709

'

'

'

'

'

Proceeds from issuance of common stock

9,451,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

Common stock shares to be issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,958,716

'

'

2,400,000

'

'

'

'

Issuance of common stock for services rendered, shares

'

'

'

'

'

1,123,033

'

'

'

'

'

'

'

'

'

'

'

1,123,033

'

'

'

'

'

'

'

'

Issuance of common stock for services rendered

'

'

'

'

'

180,100

'

'

'

'

'

'

'

'

'

'

'

1,123

'

'

'

'

'

'

'

'

Number of shares to be purchased

'

'

'

41,203,791

'

41,203,791

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise price per share

$0.50

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options exercisable

'

'

'

2,466,300

'

2,466,300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable - weighted average exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.12

'

'

'

'

'

Common stock shares reserved for future issuance

'

'

'

2,451,070

'

2,451,070

'

'

'

'

'

'

'

'

'

'

'

'

6,460,000

'

'

'

'

'

'

'

Stock-based compensation expense

'

'

'

'

'

150,000

'

'

'

'

'

20,000

130,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,634,615

57,690

'

'

'

'

'

Promissory notes, aggregate principal amount

'

'

$1,098,000

'

$745,000

'

$745,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common shares issued in exchange for convertible notes

'

'

9,486,720

'

'

8,046,000

'

'

'

'

'

'

'

8,784,000

7,450,000

702,720

596,000

'

'

'

'

'

'

'

'

'

STOCKHOLDERS_EQUITY_DEFICIT_Su

STOCKHOLDERS' EQUITY (DEFICIT) (Summary of Stock Option Activity) (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Shares	'	'
Outstanding, beginning balance	47,923,642	'
Granted	16,135,000	'
Cancelled	-5,695,250	'
Exercised	-2,466,300	'
Expired	-51,809	'
Outstanding, ending balance	55,845,283	47,923,642
Weighted Average Exercise Price per Share	'	'
Outstanding, beginning balance	$0.20	'
Granted	$0.20	'
Cancelled	$0.13	'
Exercised	$0.04	'
Expired	$0.83	'
Outstanding, ending balance	$0.21	$0.20
Weighted Average Remaining Contractual Life (Years)	'	'
Outstanding, beginning balance	'6 years 3 months 18 days	'5 years 1 month 6 days
Granted	'9 years 1 month 6 days	'
Cancelled	'7 years 7 months 6 days	'
Exercised	'3 years 7 months 6 days	'
Outstanding, ending balance	'6 years 3 months 18 days	'5 years 1 month 6 days

STOCKHOLDERS_EQUITY_DEFICIT_Su1

STOCKHOLDERS' EQUITY (DEFICIT) (Summary of Status of Non-Vested Options) (Details) (USD $)	9 Months Ended
	Sep. 30, 2014
Shares	'
Non-vested, beginning balance	13,418,000
Granted	16,135,000
Cancelled	-4,861,250
Vested	-2,412,250
Non-vested, ending balance	22,279,500
Weighted Average Grant Date Fair Value	'
Non-vested, beginning balance	$0.03
Granted	$0.06
Cancelled	$0.03
Vested	$0.04
Non-vested, ending balance	$0.05

STOCKHOLDERS_EQUITY_DEFICIT_Wa

STOCKHOLDERS' EQUITY (DEFICIT) (Warrants to Purchase Common Stock) (Details) (USD $)

Sep. 30, 2014

Mar. 07, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Warrant 1

Warrant 2

Warrant 3

Warrant 4

Warrant 5

Warrant 6

Warrant 7

Warrant 8

Warrant 9

Warrant 10

Warrant 11

Warrant 12

Warrant 13

Warrant 14

Warrant 15

Warrant 16

Warrant 17

Warrant 18

Stockholders Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Shares To be Purchased

41,203,791

'

1,750,000

1,600,000

1,333,333

490,000

196,000

163,333

500,000

200,000

166,667

700,000

1,540,000

1,416,666

240,125

1,166,667

4,392,000

3,725,000

20,400,000

1,224,000

Warrant Exercise Price per Share

'

$0.50

$0.10

$0.13

$0.15

$0.10

$0.13

$0.15

$0.10

$0.13

$0.15

$0.10

$0.13

$0.15

$1.25

$0.18

$0.15

$0.13

$0.31

$0.30

Warrant Expiration Date

'

'

'August 16, 2015

'August 16, 2015

'August 16, 2015

'October 22, 2015

'October 22, 2015

'October 22, 2015

'November 19, 2015

'November 19, 2015

'November 19, 2015

'February 15, 2016

'February 15, 2016

'February 15, 2016

'October 24, 2016

'February 10, 2017

'June 21, 2018

'September 30, 2018

'March 11, 2019

'March 11, 2019

WARRANT_LIABILITY_Schedule_of_

WARRANT LIABILITY (Schedule of Warranty Liability) (Details) (USD $)	0 Months Ended		3 Months Ended		9 Months Ended
	Mar. 07, 2014	Mar. 11, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
WARRANT LIABILITY [Abstract]	'	'	'	'	'	'
Number of shares underlying the warrants	20,400,000	20,400,000	20,400,000	'	20,400,000	'
Exercise price	$0.31	$0.31	$0.31	'	$0.31	'
Volatility	'	28.30%	'	'	28.30%	'
Risk free interest rate	'	1.62%	'	'	1.60%	'
Expected dividend yield	'	0.00%	'	'	0.00%	'
Expected warrant life (years)	'5 years	'5 years	'	'	'4 years 5 months 8 days	'
Stock Price	'	$0.24	$0.22	'	$0.22	'
Fair value of warrant liability upon issuance	'	'	'	'	$862,920	'
Change in warrant liability	'	'	($234,600)	'	($208,080)	'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) (USD $)	0 Months Ended	9 Months Ended	1 Months Ended	9 Months Ended
	Aug. 11, 2003	Sep. 30, 2014	Sep. 30, 2006	Sep. 30, 2014
	Royalty Agreements [Member]	Royalty Agreements [Member]	License Agreement [Member]	License Agreement [Member]
Commitments and Contingencies Disclosure [Line Items]	'	'	'	'
Equity investment by an existing investor	$4,000,000	'	'	'
Future royalty payment percentage on gross gross revenue	3.00%	'	'	'
Royalty cost	'	$68,000	'	$57,000
Term of License Agreement	'	'	'18 years	'
Royalty rate, lower limit	'	'	2.50%	'
Royalty rate, upper limit	'	'	5.00%	'

NET_LOSS_PER_SHARE_Details

NET LOSS PER SHARE (Details)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Stock Options and Warrants [Member]	'	'
Earnings Per Share Basic [Line Items]	'	'
Number of shares excluded from the calculation of diluted loss per share	97,049,000	74,289,000
Convertible Series A and Series B Preferred Stock [Member]	'	'
Earnings Per Share Basic [Line Items]	'	'
Number of shares excluded from the calculation of diluted loss per share	234,478,000	215,310,000
Convertible Notes [Member]	'	'
Earnings Per Share Basic [Line Items]	'	'
Number of shares excluded from the calculation of diluted loss per share	0	16,234,000

SUBSEQUENT_EVENTS_Details

SUBSEQUENT EVENTS (Details) (USD $)

Sep. 30, 2014

Mar. 11, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Nov. 06, 2014

Oct. 09, 2014

Oct. 09, 2014

Oct. 09, 2014

Oct. 09, 2014

Oct. 09, 2014

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series A Preferred Stock [Member]

Series B Preferred Stock [Member]

Minimum [Member]

Maximum [Member]

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Divided rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

Preferred stock, par value (in dollars per share)

'

'

'

$0.00

$0.00

'

$0.00

$0.00

'

'

'

'

'

'

Preferred stockholders percentage who elect to convert into common Stock

'

'

'

'

'

'

'

'

'

'

80.00%

'

'

'

Common stock, par value (in dollars per share)

$0.00

'

'

'

'

'

'

'

'

'

$0.00

'

'

'

Conversion price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

$1.25

$0.77

$0.04

Effectiveness of the Preferred Stock Series Amendment, the percent of preferred stockholders, who elect to convert into Common Stock

'

'

'

'

'

'

'

'

'

'

88.00%

'

'

93.00%

Stated value (in dollars per share)

$0.22

$0.24

'

'

'

'

'

'

'

$100

'

'

'

'

Number of shares converted into common stock

'

'

'

0

0

'

'

'

'

92,712.27

1,894,969

'

'

84,283.99

Number of common stock issued upon conversion

'

'

'

'

'

'

'

'

'

'

2,583,289

'

'

256,111,243

Preferred stock, shares issued

'

'

'

1,894,969

'

1,759,666

84,283.99

79,336.54

'

0

'

'

'

'

Preferred stock, shares outstanding

'

'

'

1,894,969

'

1,759,666

84,283.99

79,336.54

'

0

'

'

'

'

Reverse split ratio

'

'

'

'

'

'

'

'

0.25

'

'

'

'

'

Common Stock, shares authorized

800,000,000

'

800,000,000

'

'

'

'

'

50,000,000

'

'

'

'

'

Undesignated preferred stock, shares authorized

100,000,000

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'